Kura Oncology Inc KURA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if KURA is a good fit for your portfolio.
News
-
Kura Oncology to Report First Quarter 2024 Financial Results
-
Kura Oncology Gets Breakthrough Designation For Leukemia Therapy
-
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
-
Kura Oncology to Participate in Stifel Targeted Oncology Forum
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $18.75
- Day Range
- $18.05–18.41
- 52-Week Range
- $7.42–24.15
- Bid/Ask
- $18.38 / $18.45
- Market Cap
- $1.40 Bil
- Volume/Avg
- 816,009 / 954,296
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 142
- Website
- https://www.kuraoncology.com
Comparables
Valuation
|
Metric
|
KURA
|
RCUS
|
IGMS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.51 | 2.52 | 2.30 |
Price/Sales | — | 9.76 | 195.50 |
Price/Cash Flow | — | — | — |
Price/Earnings
KURA
RCUS
IGMS
Financial Strength
|
Metric
|
KURA
|
RCUS
|
IGMS
|
|---|---|---|---|
Quick Ratio | 12.02 | 4.35 | 7.95 |
Current Ratio | 12.26 | 4.52 | 8.18 |
Interest Coverage | −107.04 | −170.00 | — |
Quick Ratio
KURA
RCUS
IGMS
Profitability
|
Metric
|
KURA
|
RCUS
|
IGMS
|
|---|---|---|---|
Return on Assets (Normalized) | −27.08% | −20.42% | −44.52% |
Return on Equity (Normalized) | −29.62% | −44.44% | −84.37% |
Return on Invested Capital (Normalized) | −31.62% | −49.53% | −77.23% |
Return on Assets
KURA
RCUS
IGMS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Frxqlvyn | Bppm | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Sqjhnrg | Vrbbx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Pzpbply | Xnmchf | $99.5 Bil | |
MRNA
| Moderna Inc | Qwpcqdfg | Dbg | $38.8 Bil | |
ARGX
| argenx SE ADR | Bfwxlvyj | Szqg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Tfqjhnyw | Wvjd | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gvxrcby | Kjctt | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Zrldvxy | Klmdsw | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Mhqrwpscgp | Zyzqy | $12.5 Bil | |
INCY
| Incyte Corp | Xyblxkmcz | Kmcfhh | $11.6 Bil |